UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

CUSIP: M96088105

Q4 2023 13F Holders as of 31 Dec 2023

Security type / class
Equity / Ordinary Shares, par value NIS 0.01 per share
Total 13F shares
21,390,291
Total 13F value
$320,854,510
Holder snapshot 6 visible 7 signals
Share change
+3,406,072
Put/Call ratio
75%
SEC-reported price per share
$15.00
Number of holders
103
Value change
+$51,912,609
Number of buys
63
Open additional details 1 more signal available
Number of sells
30
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
48,684,257

Security key

M96088105

Report period

Q4 2023

Institutions

103

Top holders

10

URGN full security history Ownership snapshot Full 13F holder table Newer quarter: Q1 2024 Previous quarter: Q3 2023 UroGen Pharma Ltd. SEC filings UroGen Pharma Ltd. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
GREAT POINT PARTNERS LLC
Disclosed value leader
GREAT POINT PARTNERS LLC
Comparable rows
15/15
Latest evidence
30 Sep 2023
13F Lead comparable stake: 5.4% Showing 1-6 of 15 holder rows.

Quick read

GREAT POINT PARTNERS LLC leads the comparable SEC ownership view at 5.4%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens GREAT POINT PARTNERS LLC's linked filing trail.
Comparable ownership Top 5
GREAT POINT PARTNERS LLC 5.4%
MENORA MIVTACHIM HOLDINGS LTD. 4.7%
RA CAPITAL MANAGEMENT, L.P. 3%
BlackRock Finance, Inc. 2.5%
CREDIT SUISSE AG/ 2.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
GREAT POINT PARTNERS LLC
13F
Company
13F
5.4%
$36,713,835
2,620,545 shares
 — 30 Sep 2023
MENORA MIVTACHIM HOLDINGS LTD.
13F
Company
13F
4.7%
$32,265,464
2,303,031 shares
 — 30 Sep 2023
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
3%
$20,786,595
1,483,697 shares
 — 30 Sep 2023
BlackRock Finance, Inc.
13F
Company
13F
2.5%
$16,779,035
1,197,647 shares
 — 30 Sep 2023
CREDIT SUISSE AG/
13F
Company
13F
2.2%
$14,850,600
1,060,000 shares
 — 30 Sep 2023
Harel Insurance Investments & Financial Services Ltd.
13F
Company
13F
1.8%
$12,191,000
870,194 shares
 — 30 Sep 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
103
Shares
21,390,291
Rows available
103
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 holders
100
Q4 2023 holders
103
Holder diff
3
Investor Q3 2023 Shares Q4 2023 Shares Share Diff Share Chg % Q3 2023 value Q4 2023 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .